Results 301 to 310 of about 351,966 (398)

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, EarlyView.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source

Humoral and functional SARS‐CoV‐2‐specific T‐cell responses elicited in chronic lymphocytic leukaemia patients with GEO‐CM04S1 a synthetic MVA‐vectored COVID‐19 vaccine

British Journal of Haematology, EarlyView.
Sandra Ortega‐Francisco, Maria Teresa Prudente de Aquino, Corinna La Rosa, Flavia Chiuppesi, Miguel‐Angel Gutierrez, Jacqueline Miller, Jing Li, Jada Mack‐Onyeike, Yifei Zhou, Qiao Zhou, Teodora Kaltcheva, Angela Patterson, Shannon Dempsey, Sandra Thomas, Katrin Tiemann, Dongyun Yang, Wasima Rida, Felix Wussow, Kelly McKee, Randy Taplitz, Erica Raiden, Tanya Siddiqi, Steven Rosen, Don J. Diamond, Alexey Danilov   +24 more
wiley   +1 more source

Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

Cancer Science, EarlyView.
Nucleoside analogs interfere with DNA replication either by their chain‐terminating properties or by serving as DNA damage on the template. The genome maintenance pathways required to maintain cellular tolerance to each nucleoside analog vary depending on the drug.
Ryotaro Kawasumi, Rubaiat E. Tabassum, Kouji Hirota   +2 more
wiley   +1 more source

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

Cancer Science, EarlyView.
The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Ryunosuke Machida, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai   +11 more
wiley   +1 more source

A Rare Initial Manifestation of Acute Lymphocytic Leukemia: Bilaterally Enlarged Kidneys and Liver

, 2009
Yalçın Başaran, Selim Sayın, Gökhan Erdem, Oral Nevruz, Ali Uğur Ural   +4 more
openalex   +2 more sources

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Donor Cell-Derived Chronic Lymphocytic Leukemia Presenting After Allogenic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Katarzyna Czempik, Izabela Noster, Joanna Dziaczkowska‐Suszek, Magdalena Głowala‐Kosińska, Dariusz Kata, Anna Kopińska, Grzegorz Helbig   +6 more
openalex   +2 more sources

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source

Immune‐related toxicity profile after haematopoietic stem cell transplantation in patients with B‐ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab

British Journal of Haematology, EarlyView.
Olayinka Okeleji, David McCall, Branko Cuglievan, Amber Gibson, Demetrios Petropoulos, Priti Tewari, Jeremy Connors, Irtiza N. Sheikh   +7 more
wiley   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

Cancer Science, EarlyView.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source